Johannes Hartwig

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14

Using on-line parameter estimation to improve efficiency of IPM machine drives

Hyun Bae Kim, Johannes Hartwig, R. D. Lorenz · 2003 · 111 citations

Engineering, Electrical Engineering, Electric Machines +16

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial

Mehdi Karoui, Claire Gallois, Guillaume Piessen et al. · Colorectal Disease · 2021 · 49 citations

Medicine, Oncology, Surgery +17

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Jean‐François Emile, Catherine Julié, Karine Le Malicot et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Immunology, Oncology +17

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability

Olivier Bouché, Thierry André, Karine Le Malicot et al. · JAMA Oncology · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17